http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 South San Francisco, Calif. and Melville, New York -- October 5, 2008 -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today announced that a randomized Phase III study... http://pharmalicensing.com/redirs/news_rss//public/news/view/444707//genentech-and-osi-pharmaceuticals-announce-topline-results-from-phase-iii-study-evaluating-the-combination-of-avastin-and-tarceva-as-second-line-treatment-for-advanced-non-small-cell-lung-cancer http://pharmalicensing.com/redirs/news_rss//public/news/view/444707//genentech-and-osi-pharmaceuticals-announce-topline-results-from-phase-iii-study-evaluating-the-combination-of-avastin-and-tarceva-as-second-line-treatment-for-advanced-non-small-cell-lung-cancer Tel Aviv, Israel - October 5, 2008 - Elron Electronic Industries Ltd. (NASDAQ & TASE: ELRN) today announced that further to its announcement on September 28, 2008 regarding Starling Advanced... http://pharmalicensing.com/redirs/news_rss//public/news/view/444724//elron-announces-purchases-of-starling-convertible-debentures http://pharmalicensing.com/redirs/news_rss//public/news/view/444724//elron-announces-purchases-of-starling-convertible-debentures Tel Aviv, October 5, 2008 - Elron Electronic Industries Ltd. (TASE & NASDAQ: ELRN), today announced that further to its announcements on May 5, August 13, and October 2, 2008, NetVision (TASE:NTSN),... http://pharmalicensing.com/redirs/news_rss//public/news/view/444725//elron-announces-that-netvision-received-notification-from-israel-antitrust-authority-regarding-agreement-to-acquire-shares-in-hot http://pharmalicensing.com/redirs/news_rss//public/news/view/444725//elron-announces-that-netvision-received-notification-from-israel-antitrust-authority-regarding-agreement-to-acquire-shares-in-hot Reykjavik, ICELAND, October 3, 2008 - deCODE genetics (Nasdaq:DCGN) today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator... http://pharmalicensing.com/redirs/news_rss//public/news/view/444638//decode-files-ind-for-dg071-a-novel-pde4-modulator-being-developed-for-alzheimers-and-other-cognitive-disorders http://pharmalicensing.com/redirs/news_rss//public/news/view/444638//decode-files-ind-for-dg071-a-novel-pde4-modulator-being-developed-for-alzheimers-and-other-cognitive-disorders KANSAS CITY, Mo. -- Oct. 3, 2008 -- Healthcare professionals from five continents, representing 13 countries, will have the opportunity to share insights and best practices in healthcare information... http://pharmalicensing.com/redirs/news_rss//public/news/view/444639//healthcare-leaders-gathering-in-kansas-city-to-collaborate-on-future-of-healthcare http://pharmalicensing.com/redirs/news_rss//public/news/view/444639//healthcare-leaders-gathering-in-kansas-city-to-collaborate-on-future-of-healthcare INDIANAPOLIS, IN and LAWRENCE, KS -October 03, 2008.ww Eli Lilly and Company (NYSE:LLY) and privately-held Deciphera Pharmaceuticals, LLC today announced that the two companies have entered into a... http://pharmalicensing.com/redirs/news_rss//public/news/view/444640//lilly-and-deciphera-pharmaceuticals-announce-licensing-and-collaboration-agreement http://pharmalicensing.com/redirs/news_rss//public/news/view/444640//lilly-and-deciphera-pharmaceuticals-announce-licensing-and-collaboration-agreement Schlieren/Basel, Switzerland and South San Francisco, California, USA - October 3, 2008 -- Genentech, Inc. (NYSE: DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX: ROG) have entered... http://pharmalicensing.com/redirs/news_rss//public/news/view/444645//genentech-glycart-and-roche-enter-into-collaboration-agreement-for-potential-cancer-therapy http://pharmalicensing.com/redirs/news_rss//public/news/view/444645//genentech-glycart-and-roche-enter-into-collaboration-agreement-for-potential-cancer-therapy South San Francisco, California, 3 October, 2008 - Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU), is pleased to announce that, as part of its ongoing fundraising activities, the Company has raised... http://pharmalicensing.com/redirs/news_rss//public/news/view/444647//fundraising http://pharmalicensing.com/redirs/news_rss//public/news/view/444647//fundraising Leiden, The Netherlands (October 3, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it received a National Institutes of Allergy and... http://pharmalicensing.com/redirs/news_rss//public/news/view/444648//crucell-receives-niaid-nih-contract-for-development-of-ebola-and-marburg-vaccines http://pharmalicensing.com/redirs/news_rss//public/news/view/444648//crucell-receives-niaid-nih-contract-for-development-of-ebola-and-marburg-vaccines Montreal, October 3, 2008 - Caprion Proteomics Inc. announced today that it has been awarded a $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of... http://pharmalicensing.com/redirs/news_rss//public/news/view/444650//this-press-release-was-issued-by-caprion-proteomics-inc-caprion-awarded-us-12-9m-infectious-disease-biomarker-research-contract http://pharmalicensing.com/redirs/news_rss//public/news/view/444650//this-press-release-was-issued-by-caprion-proteomics-inc-caprion-awarded-us-12-9m-infectious-disease-biomarker-research-contract